Effect of circulation on the disposition and ocular tissue distribution of 20 nm nanoparticles after periocular administration

Molecular Vision

Volumn 14, Issue , 2008, Pages 150-160

  Amrite, Aniruddha C ^a,d   Edelhauser, Henry F ^c   Singh, Swita R ^a   Kompella, Uday B ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c EMORY EYE CENTER   (United States)

^d IQVIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; NANOPARTICLE; SURFACTANT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AXILLARY LYMPH NODE; CERVICAL LYMPH NODE; CHOROID; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DISPOSITION; DRUG RELEASE; DRUG TISSUE LEVEL; EYE BLOOD FLOW; ISOLATED LIVER; LYMPH FLOW; MATHEMATICAL MODEL; MESENTERY LYMPH NODE; NONHUMAN; PERMEABILITY; PRIORITY JOURNAL; RAT; RETICULOENDOTHELIAL SYSTEM; RETINA; SCLERA; SPLEEN; TISSUE DISTRIBUTION; TISSUE SECTION; VITREOUS BODY;

ANIMALS; BIOLOGICAL TRANSPORT; CATTLE; CHOROID; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION ROUTES; EYE; LYMPH NODES; MICROSCOPY, CONFOCAL; NANOPARTICLES; PARTICLE SIZE; PERMEABILITY; PIGMENT EPITHELIUM OF EYE; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; REGIONAL BLOOD FLOW; RETINA; SCLERA; SULFONAMIDES; TISSUE DISTRIBUTION;

EID: 38849152122     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Raghava S, Hammond M, Kompella UB. Periocular routes for retinal drug delivery. Expert Opin Drug Deliv 2004; 1:99-114.
2. Slakter JS. Anecortave acetate for treating or preventing choroidal neovascularization. Ophthalmol Clin North Am 2006; 19:373-80.
3. Slakter JS, Bochow TW, D'Amico DJ, Marks B, Jerdan J, Sullivan EK, Robertson SM, Slakter JS, Sullins G, Zilliox P, Anecortave Acetate Clinical Study Group. Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfoveal neovascularization in age-related macular degeneration. Ophthalmology 2006; 113:3-13.
4. Ambati J, Gragoudas ES, Miller JW, You TT, Miyamoto K, Delori FC, Adamis AP. Transscleral delivery of bioactive protein to the choroid and retina. Invest Ophthalmol Vis Sci 2000; 41:1186-91.
5. Kim TW, Lindsey JD, Aihara M, Anthony TL, Weinreb RN. Intraocular distribution of 70-kDa dextran after subconjunctival injection in mice. Invest Ophthalmol Vis Sci 2002; 43:1809-16.
6. Amrite AC, Kompella UB. Nanoparticles for ocular drug delivery. In: Gupta RB, Kompella UB, editors. Nanoparticle technology for drug delivery. New York: Taylor and Francis; 2006. p. 319-60.
7. Kothuri MK, Pinnamaneni S, Das NG, Das SK. Microparticles and nanoparticles in ocular drug delivery. In: Mitra AK, editor. Ophthalmic Drug Delivery Systems. New York: Marcel-Dekker; 2003. p. 437-66.
8. Yasukawa T, Kimura K Tabata Y, Ogura Y. Biodegradable scleral plugs for vitreoretinal drug delivery. Adv Drug Deliv Rev 2001; 52:25-36:
9. Yasukawa T, Ogura Y, Sakurai E, Tabata Y, Kimura H. Intraocular sustained drug delivery using implantable polymeric devices. Adv Drug Deliv Rev 2005; 57:2033-46.
10. Yasukawa T, Ogura Y, Tabata Y, Kimura H, Wiedemann P, Honda Y. Drug delivery systems for vitreoretinal diseases. Prog Retin Eye Res 2004; 23:253-81.
11. Vasir JK, Labhasetwar V. Biodegradable nanoparticles for cytosolic delivery of therapeutics. Adv Drug Deliv Rev 2007; 59:718-28.
12. Amrite AC, Kompella UB. Size-dependent disposition of nanoparticles and microparticles following subconjunctival administration. J Pharm Pharmacol 2005; 57:1555-63.
13. Kim SH, Lutz RJ, Wang NS, Robinson MR. Transport Barriers in Transscleral Drug Delivery for Retinal Diseases. Ophthalmic Res 2007; 39:244-54.
14. Kompella UB, Bandi N, Ayalasomayajula SP. Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression. Invest Ophthalmol Vis Sci 2003; 44:1192-201.
15. Amrite AC, Edelhauser HF, Kompella UB. Modeling of corneal and retinal pharmacokinetics following periocular administration. Invest Ophthalmol Vis Sci. In press.
16. Cheruvu NP, Kompella UB. Bovine and porcine transscleral solute transport: influence of lipophilicity and the Choroid-Bruch's layer. Invest Ophthalmol Vis Sci 2006; 47:4513-22.
17. Ayalasomayajula SP, Kompella UB. Retinal delivery of celecoxib is several-fold higher following subconjunctival administration compared to systemic administration. Pharm Res 2004; 21:1797-804.
18. CheruvuNPAmriteACKompellaUBEffect of eye pigmentation on trans-scleral drug delivery.Invest Ophthalmol Vis SciIn press2007
19. Sasaki H, Kashiwagi S, Mukai T, Nishida K, Nakamura J, Nakashima M, Ichikawa M. Topical delivery system of ophthalmic drugs by periocular injection with viscous solution. Biol Pharm Bull 1999; 22:961-5.
20. Sasaki H, Kashiwagi S, Mukai T, Nishida K, Nakamura J, Nakashima M, Ichikawa M. Drug absorption behavior after periocular injections. Biol Pharm Bull 1999; 22:956-60.
21. Wine NA, Gornall AG, Basu PK. The ocular uptake of subconjunctivally injected. 14C-hydrocortisone. Am J Ophthalmol 1964; 58:362-6.
22. Kompella UB, Sundaram S, Raghava S, Escobar ER. Luteinizing hormone-releasing hormone agonist and transterrin functionalizations enhance nanoparticle delivery in a novel bovine ex vivo eye model. Mol Vis 2006; 12:1185-98.
23. Levy JH. Intraocular sporotrichosis. Report of a case. Arch Ophthalmol 1971; 85:574-9.
24. Polse KA, Keener RJ, Jauregui MJ. Dose-response effects of corneal anesthetics. Am J Optom Physiol Opt 1978; 55:8-14.
25. Smolen VF, Siegel FP. Procaine interaction with the corneal surface and its relation to anesthesia. J Pharm Sci 1968; 57:378-84.
26. Tsuji A, Tamai I, Sasaki K. Intraocular penetration kinetics of prednisoione after subconjunctival injection in rabbits. Ophthalmic Res 1988; 20:31-43.
27. Bourges JL, Gautier SE, Delie F, Bejjani RA, Jeanny JC, Gurny R, BenEzra D, Behar-Cohen FF. Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles. Invest Ophthalmol Vis Sci 2003; 44:3562-9.
28. Bejjani RA, BenEzra D, Cohen H, Rieger J, Andrieu C, Jeanny JC, Gollomb G, Behar-Cohen FF. Nanoparticles for gene delivery to retinal pigment epithelial cells. Mol Vis 2005; 11:124-32.
29. Geze A, Chau LT, Choisnard L, Mathieu JP, Marti-Batlle D, Riou L, Putaux JL, Wouessidjewe D. Biodistribution of intravenously administered amphiphilic beta-cyclodextrin nanospheres: Int. J Pharm 2007; 344:135-42.
30. Schipper ML, Cheng Z, Lee SW, Bentolila LA, Iyer G, Rao J, Chen X, Wu AM, Weiss S, Gambhir SS. microPET-based biodistribution of quantum dots in living mice. J Nucl Med 2007; 48:1511-8.
31. Liu H, Meagher CK, Moore CP, Phillips TE. M cells in the follicle-associated epithelium of the rabbit conjunctiva preferentially bind and translocate latex beads. Invest Ophthalmol Vis Sci 2005; 46:4217-23.
32. Camelo S, Shanley A, Voon AS, McMenamin PG. The distribution of antigen in lymphoid tissues following its injection into the anterior chamber of the rat eye. J Immunol 2004; 172:5388-95.
33. Amrite AC, Ayalasomayajula SP, Cheruvu NP, Kompella UB. Single periocular injection of celecoxib-PLGA microparticles inhibits diabetes-induced elevations in retinal PGE2, VEGF, and vascular leakage. Invest Ophthalmol Vis Sci 2006; 47:1149-60.
34. Ayalasomayajula SP, Kompella UB. Subconjunctivally administered celecoxib-PLGA microparticles sustain retinal drug levels and alleviate diabetes-induced oxidative stress in a rat model. Eur J Pharmacol 2005; 511:191-8.